These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20720351)

  • 1. A case of severe thrombocytopenia in a patient with chronic hepatitis C caused by a single administration of pegylated interferon α 2a subsequent to 48 weeks of pegylated interferon α 2b plus ribavirin therapy.
    Kato H; Fujishiro T; Narita M
    Intern Med; 2010; 49(16):1741-4. PubMed ID: 20720351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy.
    Homoncik M; Sieghart W; Formann E; Schmid M; Ferenci P; Gangl A; Jilma B; Peck-Radosavljevic M
    Am J Gastroenterol; 2006 Oct; 101(10):2275-82. PubMed ID: 17032193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
    Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
    J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.
    Laguno M; Cifuentes C; Murillas J; Veloso S; Larrousse M; Payeras A; Bonet L; Vidal F; Milinkovic A; Bassa A; Villalonga C; Pérez I; Tural C; Martínez-Rebollar M; Calvo M; Blanco JL; Martínez E; Sánchez-Tapias JM; Gatell JM; Mallolas J
    Hepatology; 2009 Jan; 49(1):22-31. PubMed ID: 19085908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
    Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
    J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)-CC genotype caused by pegylated interferon (IFN)-α-2a with ribavirin therapy: a case report.
    Jiang W; Hidaka H; Nakazawa T; Kitagawa H; Koizumi W
    BMC Res Notes; 2014 Mar; 7():141. PubMed ID: 24621321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incident severe thrombocytopenia in veterans treated with pegylated interferon plus ribavirin for chronic hepatitis C infection.
    Hermos JA; Quach L; Gagnon DR; Weber HC; Altincatal A; Cho K; Lawler EV; Grotzinger KM
    Pharmacoepidemiol Drug Saf; 2014 May; 23(5):480-8. PubMed ID: 24677630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
    Mira JA; López-Cortés LF; Merino D; Arizcorreta-Yarza A; Rivero A; Collado A; Ríos-Villegas MJ; González-Serrano M; Torres-Tortoso M; Macías J; Valera-Bestard B; Fernández-Fuertes E; Girón-González JA; Lozano F; Pineda JA;
    Antivir Ther; 2007; 12(8):1225-35. PubMed ID: 18240862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C.
    Sagir A; Wettstein M; Heintges T; Häussinger D
    Dig Dis Sci; 2002 Mar; 47(3):562-3. PubMed ID: 11911342
    [No Abstract]   [Full Text] [Related]  

  • 11. Peginterferon (PEG-IFN) plus ribavirin combination therapy, but neither interferon nor PGE-IFN alone, induced type 1 diabetes in a patient with chronic hepatitis C.
    Ogihara T; Katagiri H; Yamada T; Kudo H; Imai J; Ishigaki Y; Hinokio Y; Yamagiwa Y; Ueno Y; Shimosegawa T; Oka Y
    Intern Med; 2009; 48(16):1387-90. PubMed ID: 19687584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
    Hashimoto Y; Kanto H; Itoh M
    J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
    Rustgi VK; Lee WM; Lawitz E; Gordon SC; Afdhal N; Poordad F; Bonkovsky HL; Bengtsson L; Chandorkar G; Harding M; McNair L; Aalyson M; Alam J; Kauffman R; Gharakhanian S; McHutchison JG;
    Hepatology; 2009 Dec; 50(6):1719-26. PubMed ID: 19852040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus.
    Tamai H; Shingaki N; Mori Y; Moribata K; Kawashima A; Maeda Y; Niwa T; Deguchi H; Inoue I; Maekita T; Iguchi M; Kato J; Ichinose M
    Gut Liver; 2016 Jul; 10(4):617-23. PubMed ID: 26601828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of vasculitis in chronic hepatitis C patient treated with pegylated interferon alpha-2a and ribavirin].
    Kim YH; Han WS; Lee SJ; Oh SN; Choi DW; Byun KS; Yeon JE
    Korean J Hepatol; 2007 Sep; 13(3):419-22. PubMed ID: 17898559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
    Gluhovschi C; Gadalean F; Kaycsa A; Curescu M; Sporea I; Gluhovschi G; Petrica L; Velciov S; Bozdog G; Bob F; Vernic C; Cioca D
    Immunopharmacol Immunotoxicol; 2011 Dec; 33(4):744-50. PubMed ID: 21320001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
    Pontali E; Angeli E; Cattelan AM; Maida I; Nasta P; Verucchi G; Caputo A; Iannacone C; Puoti M
    Antivir Ther; 2015; 20(1):39-48. PubMed ID: 24831457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.
    Wirth S; Ribes-Koninckx C; Calzado MA; Bortolotti F; Zancan L; Jara P; Shelton M; Kerkar N; Galoppo M; Pedreira A; Rodriguez-Baez N; Ciocca M; Lachaux A; Lacaille F; Lang T; Kullmer U; Huber WD; Gonzalez T; Pollack H; Alonso E; Broue P; Ramakrishna J; Neigut D; Valle-Segarra AD; Hunter B; Goodman Z; Xu CR; Zheng H; Noviello S; Sniukiene V; Brass C; Albrecht JK
    J Hepatol; 2010 Apr; 52(4):501-7. PubMed ID: 20189674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha induced severe thrombocytopenia: a case report and review of the literature.
    Li L; Han DK; Lu J
    World J Gastroenterol; 2010 Mar; 16(11):1414-7. PubMed ID: 20238410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.